#obesity-treatment

[ follow ]
#weight-loss-drugs
Healthcare
fromwww.mercurynews.com
4 months ago

Patients struggle with lack of consistent coverage for popular weight-loss drugs

Access to obesity treatments is hindered by inconsistent insurance coverage and high costs, making it difficult for many to maintain weight loss.
Medicine
fromtime.com
2 months ago

Medicare Will Not Cover GLP-1 Drugs for Weight Loss

Medicare and Medicaid will not cover weight-loss drugs for obesity treatment, affecting millions.
Healthcare
fromwww.mercurynews.com
4 months ago

Patients struggle with lack of consistent coverage for popular weight-loss drugs

Access to obesity treatments is hindered by inconsistent insurance coverage and high costs, making it difficult for many to maintain weight loss.
Medicine
fromtime.com
2 months ago

Medicare Will Not Cover GLP-1 Drugs for Weight Loss

Medicare and Medicaid will not cover weight-loss drugs for obesity treatment, affecting millions.
fromwww.independent.co.uk
1 week ago

Poll: Should weight loss drugs be widely available on the NHS?

We believe quality journalism should be available to everyone, paid for by those who can afford it.
UK news
#weight-loss
Wearables
fromwww.mercurynews.com
1 month ago

Zepbound trims more belly fat than Wegovy, study shows

Eli Lilly's Zepbound outperformed Novo Nordisk's Wegovy in a recent study, showing superior weight loss and waist circumference reduction.
Wearables
fromBusiness Insider
2 months ago

Weight loss in a pill? Eli Lilly just took a big step closer to making it happen

Orforglipron, a new oral GLP-1 drug from Eli Lilly, may transform obesity treatment by offering a non-injection alternative.
Wearables
fromwww.mercurynews.com
1 month ago

Zepbound trims more belly fat than Wegovy, study shows

Eli Lilly's Zepbound outperformed Novo Nordisk's Wegovy in a recent study, showing superior weight loss and waist circumference reduction.
Wearables
fromBusiness Insider
2 months ago

Weight loss in a pill? Eli Lilly just took a big step closer to making it happen

Orforglipron, a new oral GLP-1 drug from Eli Lilly, may transform obesity treatment by offering a non-injection alternative.
fromNature
3 weeks ago

How to keep weight off after obesity drugs

Sheree's struggle emphasizes the increasing reliance on non-traditional methods for weight management amidst the challenges presented by GLP-1 therapies.
Alternative medicine
#diabetes
OMG science
fromHarvard Gazette
1 month ago

How a fishing expedition helped lead to GLP-1 - Harvard Gazette

GLP-1's discovery has revolutionized the treatment of obesity and diabetes.
Unexpected research paths can lead to significant medical advancements.
OMG science
fromHarvard Gazette
1 month ago

How a fishing expedition helped lead to GLP-1 - Harvard Gazette

GLP-1's discovery has revolutionized the treatment of obesity and diabetes.
Unexpected research paths can lead to significant medical advancements.
#glp-1-receptor-agonists
Alternative medicine
fromenglish.elpais.com
2 months ago

The Ozempic universe expands: These drugs also treat fatty liver disease

Ozempic drugs show promise in treating fatty liver disease, halting or reversing its progression, and may provide broader therapeutic effects beyond weight loss.
US news
fromBoston.com
4 months ago

Could obesity drugs help with alcohol cravings? New study suggests potential

GLP-1 receptor agonists show potential in reducing alcohol cravings but safety for non-obese individuals remains uncertain.
#clinical-trials
Wearables
fromwww.nytimes.com
2 months ago

What to Know About Eli Lilly's Daily Pill for Weight Loss

Eli Lilly's orforglipron offers a potential oral treatment for obesity and diabetes, expanding access beyond current injected options.
Wearables
fromtime.com
2 months ago

Pfizer Ends Development of Its Obesity Pill

Pfizer has halted the development of danuglipron due to safety concerns, but remains committed to exploring other obesity treatment options.
Wearables
fromwww.nytimes.com
2 months ago

What to Know About Eli Lilly's Daily Pill for Weight Loss

Eli Lilly's orforglipron offers a potential oral treatment for obesity and diabetes, expanding access beyond current injected options.
Wearables
fromtime.com
2 months ago

Pfizer Ends Development of Its Obesity Pill

Pfizer has halted the development of danuglipron due to safety concerns, but remains committed to exploring other obesity treatment options.
Healthcare
fromFast Company
2 months ago

Trump scraps Biden's plan to cover Wegovy and Zepbound through Medicare

Trump administration's decision excludes expensive obesity treatments from Medicare coverage.
Medicine
fromwww.nytimes.com
2 months ago

Trump Rejects Proposal for Medicare to Cover Wegovy and Other Obesity Drugs

Trump administration rejects Biden's proposal on obesity drug coverage for Medicare and Medicaid.
#tirzepatide
Healthcare
fromwww.npr.org
3 months ago

Consumers can buy Zepbound direct from the drugmaker if they'll pay out of pocket

Eli Lilly's Zepbound reaches 100,000 direct buyers monthly, showing a shift towards online drug sales despite insurance coverage limitations.
fromwww.theguardian.com
7 months ago

Exercise in a pill: have scientists really found a drug that's as good for you as a 10km run?

Researchers have developed drugs known as mimetics that aim to replicate the beneficial effects of exercise. One such drug, LaKe, induces a metabolic state similar to high-intensity running.
Exercise
fromArs Technica
10 months ago

Eli Lilly raises price of Zepbound while trumpeting discount on starter vials

Eli Lilly's new offering of Zepbound in vials at significantly lower prices compared to its injectable pens reflects its commitment to improve access for obesity treatments.
Medicine
[ Load more ]